Association of Anxiety Symptoms in Offspring of Bipolar Parents with Serotonin Transporter-Linked Polymorphic Region (5-HTTLPR) Genotype

Min-Hyeon Park, MD, PhD,¹ Erica Sanders, BA,² Meghan Howe, LCSW, MSW,² Manpreet Singh, MD, MS,² Joachim Hallmayer, MD, PhD,² Eunjoo Kim, MD,³ and Kiki Chang, MD²

Abstract

Objective: Offspring of parents with bipolar disorder (BD) have been shown to be at high risk for BD. Anxiety symptoms, even at subclinical levels, have been associated with increased risk for BD in these youth. The *s*-allele of the serotonin transporter-linked polymorphic region (5-HTTLPR) has been implicated in the pathophysiology of both BD and anxiety disorders and has been associated with pharmacological treatment response and increased risk for antidepressant side effects. Therefore, we aimed to explore 1) whether anxiety symptoms in offspring of BD parents were associated with presence of the 5-HTTLPR *s*-allele and 2) whether anxiety symptoms in the offspring of BD parents according to the 5-HTTLPR genotypes are related to antianxiety medication status.

Methods: A total of 64 offspring of BD parents (mean age: 13.7 years) and 51 healthy controls (HC) (mean age: 13.7 years) were compared genetically and on the Multidimensional Anxiety Scale for Children (MASC).

Results: Offspring of BD parents showed higher levels of overall anxiety than did the HC group. Only antianxiety medication naïve offspring of BD parents were found to have an association between 5-HTTLPR genotypes and anxiety symptoms. The antianxiety medication naïve offspring of BD parents with the *s*-allele showed higher level of overall anxiety than offspring of BD parents with the *l/l* genotype. No significant differences in anxiety symptoms or their association with the 5-HTTLPR genotype were found in the HC group.

Conclusions: This study indicated that there may be an association between 5-HTTLPR genotypes and anxiety symptoms in offspring of BD parents, and that antianxiety medication status may affect anxiety symptoms in the offspring of BD patients according to genotype.

Introduction

CHILDREN OF PARENTS WITH BIPOLAR DISORDER (BD) (offspring of BD parents) have been shown to be at high risk for developing BD (DelBello and Geller 2001; Chang et al. 2003a) and other psychiatric disorders (Lapalme et al. 1997; Singh et al. 2007). Among the various psychiatric comorbidities in offspring of BD parents, anxiety disorders have attracted special attention not only because of their high prevalence rate in offspring of BD parents but also because the presence of anxiety disorders may serve as a predictor for developing BD (Chang et al. 2003a; Henin et al. 2005; Sala et al. 2014). Even subclinical levels of anxiety can predispose individuals to developing BD, suggesting that having early anxiety symptoms in BD offspring may represent an endophenotype of BD (Contreras et al. 2010).

The serotonin transporter gene (SLC6A4) has been implicated in the pathophysiology of anxiety disorders (Lesch et al. 1996; Lapalme, et al. 1997; Hariri et al. 2002; Heinz et al. 2005; Munafò et al. 2008; Surguladze et al. 2008) and mood disorders including BD (Cho et al. 2005; Kenna et al. 2012). The serotonin transporter-linked polymorphic region (5-HTTLPR) is the most studied serotonergic gene polymorphism in psychiatric behavioral genetics (Margoob and Mushtaq 2011). The *l*-allele of the 5-HTTLPR is associated with a relative acceleration of serotonin reuptake and the subsequent decreased concentration of serotonin in synapse, whereas the *s*-allele is associated with decreased serotonin reuptake (Lesch et al. 1996). Most studies that have examined the association between the response to selective serotonin reuptake inhibitors (SSRIs) and the 5-HTTLPR genotypes in patients with depression or anxiety have reported that the *s/s* genotype or *s*-allele is related to

¹Department of Psychiatry, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Seoul, St. Mary's Hospital, Korea.

²Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.

³Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea.

Funding: This study was funded by the National Institute of Mental Health (NIMH) (R01 MH077047 and K23 MH064460 to Dr. Chang and K23 MH085919 to Dr. Singh).

a poor response, because serotonin transporter activity is depressed; therefore, if additional SSRIs are administered, it is impossible to expect an additional decrease in serotonin transporter activity because of the floor effect (Murphy et al. 2004). Serotonin receptors are a common target of pharmacotherapy for anxiety (Roerig 1999) and mood disorders (Kenna et al. 2012). Furthermore, the serotonin transporter (5-HTT) is abundantly distributed throughout the brain and most highly expressed in medial structures such as the amygdala (Du et al. 2000), which is principally involved in anxiety states and emotional regulation (Davidson 2002).

Although anxiety symptoms may serve as a predisposing factor for BD development in offspring of BD parents, and the 5-HTTLPR polymorphism is thought to be implicated in both BD and anxiety, no previous study has investigated the relation between anxiety symptoms and the 5-HTTLPR genotype in offspring of BD parents. Furthermore, the 5-HTTLPR genotype may moderate antianxiety medication response and risk for adverse effects (Kronenberg et al. 2007).

Therefore, we aimed to examine 1) whether the offspring of BD parents group would show higher anxiety than the healthy control (HC) group, 2) whether the 5-HTTLPR *s*-allele is associated with higher anxiety symptoms, and 3) whether anxiety symptoms in the offspring of BD parents are affected by their antianxiety medication status, according to the 5-HTTLPR genotype.

Methods

Participants

The protocol was approved by the Stanford University Panel of Medical Research in Human Subjects. One hundred BD offspring and 60 HC were recruited from an ongoing study of youth at risk for BD and from the community. After obtaining oral and written informed consent and assent from parents from their offspring, respectively, we conducted semistructured interviews to assess for BD in parents and psychopathology in their offspring. Parents were diagnosed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) (First et al. 1996), and were interviewed for psychiatric history of first- and second-degree relatives following the Family History-Research Diagnostic Criteria (FH-RDC) (Andreasen et al. 1977). BD offspring were assessed using the Affective Disorders Module of the Washington Schedule for Affective Disorders and Schizophrenia for School-Age Children (WASH-U-KSADS) (Geller et al. 2001) and Kiddie-SADS-Present and Lifetime Version (K-SADS-PL) (Kaufman et al. 1997). All evaluations were conducted by either a child and adolescent psychiatrist or a trained master's level research assistant with at least 2 years' experience in psychiatric interviewing. Evaluators were aware of parental diagnoses, and parents were interviewed while they were euthymic at the time of their child's assessment. Interrater reliability was established by rating videotaped interviews, observing trained rater interviews, and performing interviews with observation by a trained rater. Diagnostic decisions were ultimately made by a board-certified child and adolescent psychiatrist (K.C. or M.S.) based on personal interview, discussion with the research assistant, and written notes of parent and offspring responses to interview questions. Current and lifetime diagnoses were established according to *Diagnostic and Statistical Manual of Mental Disorders*, 4th ed. (DSM-IV) criteria (American Psychiatric Association 1994).

Youth 9–17 years of age who had at least one biological parent with BD were included in the BD offspring group. BD offspring with the following disorders or conditions were excluded: BD I or

II, schizophrenia, pervasive developmental disorder, Tourette's disorder, substance use disorder, obsessive-compulsive disorder (OCD), panic disorder, or a neurological condition (such as a seizure disorder). HC had no personal or parental psychiatric history and no family history of BD, and were excluded with current Young Mania Rating Scale (YMRS) (Young et al. 1978) scores >8 or Childhood Depression Rating Scale (CDRS-R) (Poznanski et al. 1985) >26.

Multidimensional Anxiety Scale for Children (MASC)

To assess anxiety symptoms, we used the MASC (March et al. 1997), a 39 item scale, distributed into four major factors: physical symptoms, social anxiety, harm avoidance, and separation anxiety. The MASC has been shown to reliably distinguish anxiety from depression, and to differentiate various anxiety disorders (Dierker et al. 1999).

Genotyping

DNA was extracted from 200 μ L of frozen blood using the QiagenDNeasy Kit (Qiagen, Hilden, Germany [Cat. #69506]). Oligonucleotide primers flanking the 5-HTT-linked polymorphic region and corresponding to the nucleotide positions –1416 to –1397 (strp5, 5'-GGC GTT GCC GCT CTG AAT GC) and –910 to –888 (strp3, 5'-GAG GGA CTG AGC TGG ACA ACC AC) of the 5-HTT gene 5'-flanking regulatory region were used to generate 484 bp or 528 bp fragments. Polymerase chain reaction (PCR) amplification was conducted in a final volume of 30 μ L, consisting of 50 ng of genomic DNA, 50 ng each of sense and antisense primers, 15 μ L of Taq PCR Master mix (Qiagen, Cat.#201445), 10% dimethyl sulfoxide (DMSO), and 1 mol/L betaine. Annealing was performed at 61°C for 30 seconds, extension was performed at 71°C for 1 minute, and denaturation was performed at 95°C for 30 seconds, for a total of 35 cycles. The PCR products were electrophoresed through 5% polyacrylamide gel (acrylamide/bis-acrylamide ratio 19:1) at 60 V for 60 minutes. A 100 bp marker was used to measure the PCR product size for the *l*- and *s*-alleles. Alleles were called by raters blind to clinical status of the participant.

Statistical analysis

To compare categorical variables, we conducted χ^2 tests. To compare continuous variables, we conducted independent *t* tests for parametric data, and Mann–Whitney *U* tests for nonparametric data. To compare subjects with different genotypes (*s/s* vs *l/s* vs *l/l*), we conducted a three way ANOVA with post-hoc Tukey (*b*) tests. The initial three groups sorted by genotype were then redivided into two groups of offspring of BD parents dichotomized by the presence of or absence of the *s*-allele. This method has been used in previous studies to determine the effect of having at least one *s*-allele (Kaufman et al. 2004, 2006). The statistical significance for all tests was set at $p < 0.05$. We corrected significance levels for multiple comparisons using a Bonferroni correction (0.05/5 comparisons = 0.01).

Results

Among 100 offspring of BD parents and 60 HC, 35 offspring of BD parents and 9 HC were excluded because of incomplete MASC data (34 offspring of BD parents and 9 HC) or genotyping failure (1 offspring of BD parents), leaving 64 offspring of BD parents (mean age, 13.7 [SD 3.45]; males = 30, females = 34) and 51 HC (mean age, 13.68 [SD 2.68]; males = 23, females = 28) to be included as subjects for statistical analysis. Among the total of 64 offspring of

BD parents, 37 (57.8%) showed subthreshold mood symptoms (YMRS > 12 or CDRS > 27). The offspring of BD parents group had significantly higher anxiety scores than HC in the physical subscale ($p=0.001$) and the social anxiety subscale ($p=0.037$), as well as in the overall MASC score ($p=0.018$). Results for the physical subscale and MASC total scores remained significant after adjusting for multiple comparisons (Fig. 1a). Participant demographic and clinical characteristics are provided in Table 1. In the offspring of BD parents group, the l/l genotype of the 5-HTTLPR was observed in 19 subjects (29.7%), the l/s genotype was observed in 30 subjects (46.9%), and the s/s genotype was observed in 15 subjects (23.4%). In the HC group, the l/l genotype was observed in 8 subjects (15.7%), the l/s genotype was observed in 28 subjects (54.9%), and the s/s genotype was observed in 15 subjects (29.4%) in the HC group. The distributions of genotypes for the 5-HTTLPR polymorphism were consistent, with expected values based on Hardy–Weinberg equilibrium in both the offspring of BD parents ($p=0.64$) and HC groups ($p=0.40$).

There was no significant difference in the current usage of antianxiety medications (Table 2) among the three 5-HTTLPR genotype groups. Similarly, there was no significant difference in the current usage of stimulant medications, which may have anxiogenic properties. Among the offspring of BD parents not currently taking antianxiety medications, no one had a past history of antianxiety medication use. In other words, there were no offspring of BD parents who had formerly taken antianxiety medication who were not current antianxiety medication users in this study. Therefore, we were able to dichotomize the offspring of BD parents group into those who were taking antianxiety medications and

TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE PARTICIPANTS

	Offspring of BD parents (n=64)	Control (n=51)	p
Age	13.73 (3.45)	13.68 (2.68)	0.93
Gender			
Male (%)	30 (46.88)	23 (45.10)	1.00
Race			
Non-Caucasian (%)	6 (9.37)	20 (39.22)	<0.001
YMRS			
Mean (SD)	6.50 (6.90)	1.10 (1.34)	<0.001
CDRS			
Mean (SD)	27.33 (11.74)	18.85 (2.24)	<0.001
MASC			
Mean (SD)			
Physical	8.05 (7.01)	4.31 (4.06)	0.01
Harm avoidance	16.41 (4.71)	15.76 (4.64)	0.47
Social anxiety	10.06 (6.14)	7.75 (5.41)	0.04
Separation anxiety	5.95 (5.24)	5.51 (4.35)	0.63
MASC Total	40.47 (17.09)	33.33 (14.24)	0.02

BD, bipolar disorder; CDRS, Children's Depression Rating Scale; MASC, Multidimensional Anxiety Scale for Children; YMRS, Young Mania Rating Scale.

FIG. 1. Anxiety symptoms differences (a) between the bipolar disorder (BD) offspring group and healthy control group (b) according to 5-HTTLPR genotype in BD offspring.

those who were antianxiety medication naïve. The offspring of BD parents who were taking antianxiety medications generally showed higher anxiety than the offspring of BD parents who were not taking antianxiety medications (Table S1) (see supplementary material in the online article at <http://www.liebertonline.com/jcap>). Nine BD offspring were taking stimulant medications, and of these subjects, five were also taking antianxiety medications. As these five subjects had already been excluded from the original analysis, we reanalyzed the data after excluding the remaining four subjects. However, no significant differences were observed when compared with the results prior to excluding stimulant medications. Four BD offspring were taking antipsychotics (three taking aripiprazole, one taking risperidone), and five BD offspring were taking lamotrigine. We performed additional analyses after excluding the subjects who were taking antipsychotics or lamotrigine, and among the subjects seven had already been excluded from the previous steps. Eventually two more subjects were excluded; however, again no significant differences were observed when compared with the results prior to excluding stimulant medications.

Comparisons by 5-HTTLPR genotype (s/s vs. l/s vs. l/l)

Analysis of the entire study group showed no significant difference in the MASC scores by 5-HTTLPR genotype. Similarly, neither the offspring of BD parents nor the HC group showed a significant difference in the MASC scores by the 5-HTTLPR genotype within each group. However, when we excluded offspring of BD parents currently taking antianxiety medication, certain trends in anxiety patterns according to genotype appeared. The antianxiety medication naïve offspring of BD parents with both the s/s ($n=15$) and l/s ($n=30$) genotypes reported higher levels of anxiety than the offspring of BD parents with the l/l ($n=19$) genotype, except in the harm avoidance subscale.

The symptom patterns observed in the offspring of BD parents were not observed in the HC group except in the social anxiety

TABLE 2. THE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS ACCORDING TO 5-HTTLPR GENOTYPE IN OFFSPRING OF BIPOLAR PARENTS

	<i>l/l</i> (<i>n</i> = 19)	<i>l/s</i> (<i>n</i> = 30)	<i>s/s</i> (<i>n</i> = 15)	<i>p</i>
Age	14.13 (3.73)	13.54 (3.22)	13.59 (3.74)	0.84
Gender				
Male (%)	8 (42.10)	17 (56.67)	5 (33.33)	0.30
Race				
Non-Caucasian (%)	1 (5.26)	4 (13.33)	1 (6.67)	0.60
YMRS				
Mean (SD)	4.50 (5.24)	8.53 (7.75)	5.73 (6.26)	0.18
CDRS				
Mean (SD)	23.21 (7.49)	31.65 (13.89)	25.09 (8.24)	0.06
BD diagnosis				
BD NOS (%)	2 (10.53)	7 (23.33)	2 (13.33)	0.46
Comorbidity				
ADHD (%)	5 (26.32)	7 (23.33)	3 (20.00)	0.91
ODD (%)	1 (5.26)	3 (10.00)	0 (0.00)	0.42
GAD (%)	5 (26.32)	7 (23.33)	1 (6.67)	0.31
Anxiety disorder NOS (%)	0 (0.00)	1 (3.33)	2 (13.33)	0.17
Phobia (%)	1 (5.26)	2 (6.67)	1 (6.67)	1.00
Antianxiety medication				
Total	6 (31.58)	6 (20.00)	2 (13.33)	0.46
SSRI	5 (26.32)	4 (13.33)	1 (6.67)	0.27
Antidepressant other than SSRI	4 (21.05)	5 (16.70)	1 (6.67)	0.55
Anxiolytic	2 (10.53)	2 (6.67)	0 (0.00)	0.56
Stimulant medication	3 (15.79)	4 (13.33)	2 (13.33)	0.74

ADHD, attention-deficit/hyperactivity disorder; BD, bipolar disorder; CDRS, Children's Depression Rating Scale; GAD, generalized anxiety disorder; NOS, not otherwise specified; ODD, oppositional defiant disorder; SSRI, selective serotonin reuptake inhibitor; YMRS, Young Mania Rating Scale.

subscale (Fig. 2), where social anxiety symptoms tended to be greater (trend) in those with the *s*-allele in both the offspring of BD parents and HC groups.

Comparisons according to presence of an *s* allele (*l/l* vs. *l/s* + *s/s*)

When dichotomized according to presence or absence of the *s*-allele (*l/l* vs. *l/s* + *s/s*), no significant difference was observed in the MASC scores according to presence of the *s*-allele in either the entire study group or the HC group. After excluding the offspring of BD parents taking antianxiety medications (*n* = 13), we examined only the remaining offspring of BD parents who were naïve to antianxiety medications (*n* = 51). Within this latter group, offspring of BD parents with at least one *s*-allele had significantly higher MASC anxiety scores than offspring of BD parents without the *s*-allele in the social anxiety subscale (*p* = 0.020), separation anxiety subscale (*p* = 0.022), and total MASC score (*p* = 0.013) (Fig. 1b). Results for the MASC total scores remained significant after adjusting for multiple comparisons (Table 3). However, when we examined only the offspring of BD parents currently taking anti-anxiety medication, no significant differences were observed in the MASC scores by presence/absence of the *s*-allele.

Discussion

In this study, the offspring of BD parents group demonstrated higher anxiety levels than the HC group, which was to be expected, given that 57.8% of the offspring of BD parent subjects were recruited for presence of mood dysregulation.

In addition, antianxiety medication naïve offspring of BD parents with at least one *s*-allele had higher reported anxiety than antianxiety medication naïve offspring of BD parents without an *s*-allele.

Concerning the relationship between BD and the 5-HTTLPR genotypes, even though some studies have shown negative results, meta-analytic results (Cho et al. 2005; Lasky-Su et al. 2005; Jiang et al. 2013) have consistently reported that the presence of the *s*-allele has a significant association with BD, albeit the effects sizes are mostly small.

Regarding the relationship between anxiety and the 5-HTTLPR genotypes, studies on anxiety manifestations below clinical disorder level, such as subclinical anxiety symptoms or anxiety traits, have shown relatively consistent results, and found that *s*-allele carriers tend to have increased anxiety-related temperament traits (Lesch et al. 1996; Mazzanti et al. 1998; Katsuragi et al. 1999; Osher et al. 2000; Melke et al. 2001; Jacob et al. 2004; Schinka et al. 2004; Sen et al. 2004; Calapoğlu et al. 2011), although a few studies have reported negative results (Willis-Owen et al. 2005; Middeldorp et al. 2007; Munafò et al. 2009) and Jorm et al. (2000) reported the *l*-allele as being a risk allele. However, the studies on clinical level anxiety disorder, such as panic disorder (Deckert et al. 1997; Ishiguro et al. 1997; Matsushita et al. 1997; Maron et al. 2005; Martinez-Barrondo et al. 2005; Blaya et al. 2007; Lonsdorf et al. 2009; Strug et al. 2010), generalized anxiety disorder (Samochowiec et al. 2004), social anxiety disorder (Strug et al. 2010), generalized social phobia (Ohara et al. 1998; Stein et al. 1998), and OCD (McDougle et al. 1998; Bengel et al. 1999; Hamilton et al. 1999) have shown conflicting results. Therefore, high scores on

FIG. 2. Anxiety symptoms according to 5-HTTLPR genotype.

TABLE 3. THE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS ACCORDING TO 5-HTTLPR IN ANTIANXIETY MEDICATION NAÏVE BD OFFSPRING

	l/l (n=13)	l/s + s/s (n=38)	p	*corrected p
Age	13.30 (3.54)	12.99 (3.10)	0.77	
Gender				
Male (%)	5 (38.46)	19 (50.00)	0.53	
Race				
Non-Caucasian (%)	0 (0.00)	4 (10.53)	0.56	
YMRS				
Mean (SD)	3.83 (5.29)	7.80 (7.63)	0.11	
CDRS				
Mean (SD)	21.50 (6.59)	28.71 (12.26)	0.06	
MASC				
Mean (SD)				
Physical	4.62 (4.17)	7.61 (6.22)	0.11	0.37
Harm avoidance	15.23 (5.36)	16.34 (4.73)	0.48	0.07
Social anxiety	5.92 (4.97)	10.58 (6.34)	0.02	0.06
Separation anxiety	3.08 (3.05)	6.95 (5.50)	0.02	0.05
MASC Total	28.85 (11.76)	41.47 (16.31)	0.01	0.02

*Corrected by CDRS.

BD, bipolar disorder; CDRS, Children's Depression Rating Scale; MASC, Multidimensional Anxiety Scale for Children; YMRS, Young Mania Rating Scale.

subscales of trait anxiety may be related to the subclinical range of anxiety symptoms that may place youth at high risk for BD.

That youth may be biologically predisposed to developing anxiety is supported by functional magnetic resonance imaging (fMRI) studies on the relationship between the 5-HTTLPR genotype and amygdala activity, which have consistently shown that *s*-allele carriers have significantly greater amygdala excitability than individuals with other genotypes (Hariri, et al. 2002; Heinz, et al. 2005; Munafò, et al. 2008; Surguladze, et al. 2008). The 5-HTTLPR genotype-mediated effect on brain region excitability was specific to the amygdala (Hariri et al. 2002), and as amygdala excitability plays a role as an intermediate phenotype of anxiety symptoms (Davidson 2002; Blackford and Pine 2012), it may be that amygdala excitability may be a mediating factor that links genotype with anxiety symptoms.

Interestingly, in our study, the association between increased anxiety and the presence of the *s*-allele was only observed in the antianxiety medication naïve offspring of BD parents group in this study. To understand this finding, we need to first comment on the characteristics of BD offspring and the role of antianxiety medication in BD offspring by the 5-HTTLPR genotype. Key gene-by-environment interactions may be leading to epigenetic modulation in BD offspring. Specifically, the BD offspring group is subject to not only genetic risk factors but also to environmental risk factors such as parent-child relationship problems that result from parents' illnesses (Chang et al. 2001). The presence of the *s*-allele of 5-HTTLPR polymorphism plays a role as a risk factor for the development of depression or anxiety, especially in individuals with stressful life events (Caspi et al. 2003; Eley et al. 2004; Kaufman et al. 2004; Kendler 2005; Kaufman et al. 2006; Stein et al. 2008; Karg et al. 2011), which are common among BD offspring (Moreno et al. 2012).

Second, one needs to consider the effect of antianxiety medications by 5-HTTLPR genotype. Except in some studies with Asian

populations (Yoshida et al. 2002; Kim et al. 2003), antidepressant effectiveness by the 5-HTTLPR genotype in adults with depression (Smeraldi et al. 1998; Pollock et al. 2000; Zanardi et al. 2000, 2001; Durham et al. 2004) and anxiety (Perna et al. 2005; Stein et al. 2006) have found that individuals with the *s/s* genotype show poorer response to antidepressants than do individuals with other 5-HTTLPR genotypes. However, a study with children and adolescents with depression and/or anxiety (Kronenberg et al. 2007) found that the *s/s* genotype was associated with poor antidepressant treatment response only to depressive symptoms but not anxiety symptoms. Further, animal studies have shown that, unlike the anxiolytic effects of antidepressants in adults (Holick et al. 2008), antidepressant exposure during adolescence appears to have anxiogenic rather than anxiolytic effects (Oh et al. 2009; Warren et al. 2011). Moreover, studies with children and adolescents with depression or anxiety disorders have reported high rates of agitation or anxiety-like symptoms during antidepressant treatment (Rey-Sánchez and Gutiérrez-Casares 1997; March et al. 1998; Ambrosini et al. 1999; Cook et al. 2001; Emslie et al. 2002; Braconnier et al. 2003; Wagner et al. 2003). For example, Kronenberg et al. (2007) found that depressed children and adolescents with the *s/s* genotype showed a low agitation rate as a side effect of citalopram treatment.

Our study showed that BD offspring treated with antianxiety medication had higher anxiety symptoms than BD offspring who were antianxiety medication naïve, suggesting that some of BD offspring might not show full response to antianxiety medication or may be vulnerable to developing anxiety-like symptoms as a side effect of treatment. Further, antianxiety medication treatment may alleviate the 5-HTTLPR genotypes' moderating effect on anxiety symptoms regardless of whether this possibility results from poor treatment response or side effects.

Finally, BD offspring with the *s*-allele had a subclinical range of anxiety symptoms. It is possible that such subclinical anxiety symptoms may represent prodromal symptoms of BD (Chang 2010). Importantly, subsyndromal manic symptoms can be mistaken for anxiety symptoms. BD offspring are at relatively high risk for the development of manic symptoms (Baumer et al. 2006; Strawn et al. 2014), and subsyndromal manic symptoms commonly first manifest as motor hyperactivity or irritability (Strawn et al. 2014). Furthermore, it is unclear whether mood instability or irritability during pharmacological treatment results from medication side effects or indicates bipolar psychopathology (Faedda et al. 2004) in BD offspring taking medications that exacerbate anxiety symptoms.

Limitations

First, although there is a high possibility of epigenetic and gene-gene interaction effect, we only examined anxiety symptoms and the 5-HTTLPR polymorphism of the 5-HTT gene in the offspring of BD parents and HC. We did not evaluate environmental risk factors such as parent-child relationships, traumatic life events, or levels of early life stress. We also did not look at other genetic polymorphisms, which may interact with the 5-HTT gene. Second, this study is a cross-sectional study that will require longitudinal follow-up to determine whether trait anxiety predicts conversion to BD in youth at familial risk. Furthermore, because of this study's cross-sectional nature and the lack of follow-up concerning the response to antianxiety medication or side effects, we could not fully investigate the alleviating effect of antianxiety medication on the 5-HTTLPR genotypes' moderating effect on anxiety symptoms. Third, the number of subjects was relatively small for genetic

analysis, and our sample contained multiple ethnic groups. However, our results did not change significantly when we re-analyzed our data after excluding non-Caucasian participants.

Conclusion

This study found an association between the 5-HTTLPR genotype and anxiety symptoms in BD offspring not exposed to anti-anxiety medications. Future longitudinal studies may confirm whether or not anxiety symptoms and certain 5-HTTLPR genotypes serve as risk factors for the development of BD in high-risk offspring. Studies that monitor symptom change in high-risk youth may capture subtle changes that may occur at a very early age. Other possible risk factors such as gene-gene interaction and genetic-environmental interactions should also be examined longitudinally. Pharmacological treatment response and side effects according to 5-HTTLPR genotype should also be explored. There have been some preliminary studies that have explored these relationships (Stein et al. 2006; Kronenberg et al. 2007). However, those studies have shown conflicting results, and the number and sample sizes of these studies are small. Finally, because BD offspring may be at high risk for manic switching, pharmacogenetic studies may aid in determining which youth are most likely to benefit from certain pharmacotherapies, and which youth may develop adverse reactions to them. Early identification of these comprehensive risk factors will enable clinicians to intervene earlier with the hope of preventing poor outcomes in these youth (Chang et al. 2003b).

Clinical Significance

This study indicated that there may be an association between 5-HTTLPR genotypes and anxiety symptoms in offspring of BD parents. Antianxiety medication status may affect anxiety symptoms in the offspring of BD patients according to genotype. Therefore, youth at high risk for BD who are not treated for anxiety may present with increased anxiety symptoms based on their 5-HTTLPR genotype. Such presentation may place them at even higher risk for development of BD.

Acknowledgments

We thank the participants who gave their time for this study.

Disclosures

Dr. Chang is a consultant for Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Sunovion, and has received research support from GlaxoSmithKline and Merck in the last two years. The other authors have nothing to disclose.

References

- Ambrosini PJ, Wagner KD, Biederman J, Glick I, Tan C, Elia J, Hebel JR, Rabinovich H, Lock J, Geller D: Multicenter open-label sertraline study in adolescent outpatients with major depression. *J Am Acad Child Adolesc Psychiatry* 38:566–572, 1999.
- American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders*, 4th ed. Washington, DC: American Psychiatric Association; 1994.
- Andreasen NC, Endicott J, Spitzer RL, Winokur G: The family history method using diagnostic criteria. Reliability and validity. *Arch Gen Psychiatry* 34:1229–1235, 1977.
- Baumer FM, Howe M, Gallelli K, Simeonova DI, Hallmayer J, Chang KD: A pilot study of antidepressant-induced mania in pediatric

- bipolar disorder: Characteristics, risk factors, and the serotonin transporter gene. *Biol Psychiatry* 60:1005–1012, 2006.
- Bengel D, Greenberg BD, Corá-Locatelli G, Altemus M, Heils A, Li Q, Murphy DL: Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder. *Mol Psychiatry* 4:463–466, 1999.
- Blackford JU, Pine DS: Neural substrates of childhood anxiety disorders: A review of neuroimaging findings. *Child Adolesc Psychiatr Clin N Am* 21:501–525, 2012.
- Blaya C, Salum GA, Lima MS, Leistner-Segal S, Manfro GG: Lack of association between the serotonin transporter promoter polymorphism (5-HTTLPR) and panic disorder: A systematic review and meta-analysis. *Behav Brain Funct* 3:41, 2007.
- Braconnier A, Le Coent R, Cohen D: Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. *J Am Acad Child Adolesc Psychiatry* 42:22–29, 2003.
- Calapoğlu M, Sahin-Calapoğlu N, Karaçöp A, Soyöz M, Elyildirim UY, Avşaroğlu S: Serotonin transporter bi- and triallelic genotypes and their relationship with anxiety and academic performance: A preliminary study. *Neuropsychobiology* 63:103–111, 2011.
- Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. *Science* 301:386–389, 2003.
- Chang K, Steiner H, Dienes K, Adleman N, Ketter T: Bipolar offspring: A window into bipolar disorder evolution. *Biol Psychiatry* 53:945–951, 2003a.
- Chang K, Steiner H, Ketter T: Studies of offspring of parents with bipolar disorder. *Am J Med Genet C Semin Med Genet* 123C:26–35, 2003b.
- Chang KD: Course and impact of bipolar disorder in young patients. *J Clin Psychiatry* 71:e05, 2010.
- Chang KD, Blasey C, Ketter TA, Steiner H: Family environment of children and adolescents with bipolar parents. *Bipolar Disord* 3:73–78, 2001.
- Cho HJ, Meira-Lima I, Cordeiro Q, Michelon L, Sham P, Vallada H, Collier DA: Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder: A systematic review and meta-analysis. *Mol Psychiatry* 10:771–781, 2005.
- Contreras J, Hare E, Pacheco A, Escamilla M, Raventos H: Is sub-clinical anxiety an endophenotype for bipolar I patients? A study from a Costa Rican sample. *J Affect Disord* 122:267–272, 2010.
- Cook EH, Wagner KD, March JS, Biederman J, Landau P, Wolkow R, Messig M: Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. *J Am Acad Child Adolesc Psychiatry* 40:1175–1181, 2001.
- Davidson RJ: Anxiety and affective style: Role of prefrontal cortex and amygdala. *Biol Psychiatry* 51:68–80, 2002.
- Deckert J, Catalano M, Heils A, Di Bella D, Friess F, Politi E, Franke P, Nothen MM, Maier W, Bellodi L, Lesch KP: Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. *Psychiatr Genet* 7:45–47, 1997.
- DelBello MP, Geller B: Review of studies of child and adolescent offspring of bipolar parents. *Bipolar Disord* 3:325–334, 2001.
- Dierker LC, Merikangas KR, Szatmari P: Influence of parental concordance for psychiatric disorders on psychopathology in offspring. *J Am Acad Child Adolesc Psychiatry* 38:280–288, 1999.
- Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD: Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. *Am J Med Genet* 96:56–60, 2000.
- Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB: The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. *Psychopharmacology (Berl)* 174:525–529, 2004.
- Eley TC, Sugden K, Corsico A, Gregory AM, Sham P, McGuffin P, Plomin R, Craig IW: Gene–environment interaction analysis of serotonin system markers with adolescent depression. *Mol Psychiatry* 9:908–915, 2004.
- Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG: Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. *J Am Acad Child Adolesc Psychiatry* 41:1205–1215, 2002.
- Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB: Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. *J Affect Disord* 82:149–158, 2004.
- First MB, Spitzer RL, Gibbon M, Williams J: Structured Clinical Interview for DSM-IV Axis I Disorders – Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
- Geller B, Zimmerman B, Williams M, Bolhofner K, Craney JL, DelBello MP, Soutullo C: Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections. *J Am Acad Child Adolesc Psychiatry* 40:450–455, 2001.
- Hamilton SP, Heiman GA, Haghighi F, Mick S, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA: Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder. *Psychiatr Genet* 9:1–6, 1999.
- Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, Weinberger DR: Serotonin transporter genetic variation and the response of the human amygdala. *Science* 297:400–403, 2002.
- Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D, Klein S, Grüsser SM, Flor H, Schumann G, Mann K, Büchel C: Amygdala–prefrontal coupling depends on a genetic variation of the serotonin transporter. *Nat Neurosci* 8:20–21, 2005.
- Henin A, Biederman J, Mick E, Sachs GS, Hirshfeld-Becker DR, Siegel RS, McMurrich S, Grandin L, Nierenberg AA: Psychopathology in the offspring of parents with bipolar disorder: A controlled study. *Biol Psychiatry* 58:554–561, 2005.
- Holick KA, Lee DC, Hen R, Dulawa SC: Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. *Neuropsychopharmacology* 33:406–417, 2008.
- Ishiguro H, Arinami T, Yamada K, Otsuka Y, Toru M, Shibuya H: An association study between a transcriptional polymorphism in the serotonin transporter gene and panic disorder in a Japanese population. *Psychiatry Clin Neurosci* 51:333–335, 1997.
- Jacob CP, Strobel A, Hohenberger K, Ringel T, Gutknecht L, Reif A, Brocke B, Lesch KP: Association between allelic variation of serotonin transporter function and neuroticism in anxious cluster C personality disorders. *Am J Psychiatry* 161:569–572, 2004.
- Jiang HY, Qiao F, Xu XF, Yang Y, Bai Y, Jiang LL: Meta-analysis confirms a functional polymorphism (5-HTTLPR) in the serotonin transporter gene conferring risk of bipolar disorder in European populations. *Neurosci Lett* 549:191–196, 2013.
- Jorm AF, Prior M, Sanson A, Smart D, Zhang Y, Easteal S: Association of a functional polymorphism of the serotonin transporter gene with anxiety-related temperament and behavior problems in children: A longitudinal study from infancy to the mid-teens. *Mol Psychiatry* 5:542–547, 2000.
- Karg K, Burmeister M, Shedden K, Sen S: The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis

- revisited: Evidence of genetic moderation. *Arch Gen Psychiatry* 68:444–454, 2011.
- Katsuragi S, Kunugi H, Sano A, Tsutsumi T, Isogawa K, Nanko S, Akiyoshi J: Association between serotonin transporter gene polymorphism and anxiety-related traits. *Biol Psychiatry* 45:368–370, 1999.
- Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry* 36:980–988, 1997.
- Kaufman J, Yang BZ, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S, Krystal JH, Gelernter J: Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. *Biol Psychiatry* 59:673–680, 2006.
- Kaufman J, Yang BZ, Douglas-Palumberi H, Houshyar S, Lipschitz D, Krystal JH, Gelernter J: Social supports and serotonin transporter gene moderate depression in maltreated children. *Proc Natl Acad Sci U S A* 101:17,316–17,321, 2004.
- Kendler KS: “A gene for...”: the nature of gene action in psychiatric disorders. *Am J Psychiatry* 162:1243–1252, 2005.
- Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J, Swift RM: Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. *Pharmacogenomics Pers Med* 5:19–35, 2012.
- Kim DK, Seo MY, Lim SW, Kim H, Kim S: Serotonin transporter gene polymorphisms and its phenotypic characteristics expressed in platelet [³H]-serotonin uptake study in Korean depressed patients. *J Korean Neuropsychiatr Assoc* 42:54–60, 2003.
- Kronenberg S, Apter A, Brent D, Schirman S, Melhem N, Pick N, Gothelf D, Carmel M, Frisch A, Weizman A: Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. *J Child Adolesc Psychopharmacol* 17:741–750, 2007.
- Lapalme M, Hodgins S, LaRoche C: Children of parents with bipolar disorder: A metaanalysis of risk for mental disorders. *Can J Psychiatry* 42:623–631, 1997.
- Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT: Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. *Am J Med Genet B Neuropsychiatr Genet* 133B:110–115, 2005.
- Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. *Science* 274:1527–1531, 1996.
- Lonsdorf TB, Rück C, Bergström J, Andersson G, Ohman A, Schalling M, Lindefors N: The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. *Prog Neuropsychopharmacol Biol Psychiatry* 33:1479–1483, 2009.
- March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J, Muller B, Riesenberger R, Rosenthal M, Sallee FR, Wagner KD, Steiner H: Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. *JAMA* 280:1752–1756, 1998.
- March JS, Parker JD, Sullivan K, Stallings P, Conners CK: The Multidimensional Anxiety Scale for Children (MASC): Factor structure, reliability, and validity. *J Am Acad Child Adolesc Psychiatry* 36:554–565, 1997.
- Margoob MA, Mushtaq D: Serotonin transporter gene polymorphism and psychiatric disorders: is there a link? *Indian J Psychiatry* 53:289–299, 2011.
- Maron E, Lang A, Tasa G, Liivlaid L, Tõru I, Must A, Vasar V, Shlik J: Associations between serotonin-related gene polymorphisms and panic disorder. *Int J Neuropsychopharmacol* 8:261–266, 2005.
- Martinez-Barrondo S, Saiz PA, Morales B, Garcia-Portilla MP, Coto E, Alvarez V, Bobes J: Serotonin gene polymorphisms in patients with panic disorder. *Actas Esp Psiquiatr* 33:210–215, 2005.
- Matsushita S, Muramatsu T, Kimura M, Shirakawa O, Mita T, Nakai T, Higuchi S: Serotonin transporter gene regulatory region polymorphism and panic disorder. *Mol Psychiatry* 2:390–392, 1997.
- Mazzanti CM, Lappalainen J, Long JC, Bengel D, Naukkarinen H, Eggert M, Virkkunen M, Linnoila M, Goldman D: Role of the serotonin transporter promoter polymorphism in anxiety-related traits. *Arch Gen Psychiatry* 55:936–940, 1998.
- McDougle CJ, Epperson CN, Price LH, Gelernter J: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. *Mol Psychiatry* 3:270–273, 1998.
- Melke J, Landén M, Baghei F, Rosmond R, Holm G, Björntorp P, Westberg L, Hellstrand M, Eriksson E: Serotonin transporter gene polymorphisms are associated with anxiety-related personality traits in women. *Am J Med Genet* 105:458–463, 2001.
- Middeldorp CM, de Geus EJ, Beem AL, Lakenberg N, Hottenga JJ, Slagboom PE, Boomsma DI: Family based association analyses between the serotonin transporter gene polymorphism (5-HTTLPR) and neuroticism, anxiety and depression. *Behav Genet* 37:294–301, 2007.
- Moreno DH, Bio DS, Petresco S, Petresco D, Gutt EK, Soeiro-de-Souza MG, Moreno RA: Burden of maternal bipolar disorder on at-risk offspring: A controlled study on family planning and maternal care. *J Affect Disord* 143:172–178, 2012.
- Munafò MR, Brown SM, Hariri AR: Serotonin transporter (5-HTTLPR) genotype and amygdala activation: A meta-analysis. *Biol Psychiatry* 63:852–857, 2008.
- Munafò MR, Freimer NB, Ng W, Ophoff R, Veijola J, Miettinen J, Järvelin MR, Taanila A, Flint J: 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. *Am J Med Genet B Neuropsychiatr Genet* 150b:271–281, 2009.
- Murphy DL, Lerner A, Rudnick G, Lesch KP: Serotonin transporter: gene, genetic disorders, and pharmacogenetics. *Mol Interv* 4:109–123, 2004.
- Oh JE, Zupan B, Gross S, Toth M: Paradoxical anxiogenic response of juvenile mice to fluoxetine. *Neuropsychopharmacology* 34:2197–2207, 2009.
- Ohara K, Nagai M, Suzuki Y, Ochiai M, Ohara K: Association between anxiety disorders and a functional polymorphism in the serotonin transporter gene. *Psychiatry Res* 81:277–279, 1998.
- Osher Y, Hamer D, Benjamin J: Association and linkage of anxiety-related traits with a functional polymorphism of the serotonin transporter gene regulatory region in Israeli sibling pairs. *Mol Psychiatry* 5:216–219, 2000.
- Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L: Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. *Neuropsychopharmacology* 30:2230–2235, 2005.
- Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. *Neuropsychopharmacology* 23:587–590, 2000.
- Poznanski EO, Freeman LN, Mokros HB: Children’s Depression Rating Scale—Revised. *Psychopharmacol Bull* 21:979–989, 1985.
- Rey-Sánchez F, Gutiérrez-Casares JR: Paroxetine in children with major depressive disorder: An open trial. *J Am Acad Child Adolesc Psychiatry* 36:1443–1447, 1997.

- Roerig JL: Diagnosis and management of generalized anxiety disorder. *J Am Pharm Assoc (Wash)* 39:811–821; quiz 877–879, 1999.
- Sala R, Strober MA, Axelson DA, Gill MK, Castro-Fornieles J, Goldstein TR, Goldstein BI, Ha W, Liao F, Iyengar S, Yen S, Hower H, Hunt J, Dickstein DP, Ryan ND, Keller MB, Birmaher B: Effects of comorbid anxiety disorders on the longitudinal course of pediatric bipolar disorders. *J Am Acad Child Adolesc Psychiatry* 53:72–81, 2014.
- Samochowiec J, Hajduk A, Samochowiec A, Horodnicki J, Stepień G, Grzywacz A, Kucharska-Mazur J: Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. *Psychiatry Res* 128:21–26, 2004.
- Schinka JA, Busch RM, Robichaux-Keene N: A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. *Mol Psychiatry* 9:197–202, 2004.
- Sen S, Burmeister M, Ghosh D: Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. *Am J Med Genet B Neuropsychiatr Genet* 127B:85–89, 2004.
- Singh MK, DelBello MP, Stanford KE, Soutullo C, McDonough-Ryan P, McElroy SL, Strakowski SM: Psychopathology in children of bipolar parents. *J Affect Disord* 102:131–136, 2007.
- Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. *Mol Psychiatry* 3:508–511, 1998.
- Stein MB, Chartier MJ, Kozak MV, King N, Kennedy JL: Genetic linkage to the serotonin transporter protein and 5HT2A receptor genes excluded in generalized social phobia. *Psychiatry Res* 81:283–291, 1998.
- Stein MB, Schork NJ, Gelernter J: Gene-by-environment (serotonin transporter and childhood maltreatment) interaction for anxiety sensitivity, an intermediate phenotype for anxiety disorders. *Neuropsychopharmacology* 33:312–319, 2008.
- Stein MB, Seedat S, Gelernter J: Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. *Psychopharmacology (Berl)* 187:68–72, 2006.
- Strawn JR, Adler CM, McNamara RK, Welge JA, Bitter SM, Mills NP, Barzman DH, Cerullo MA, Chang KD, Strakowski SM, DelBello MP: Antidepressant tolerability in anxious and depressed youth at high risk for bipolar disorder: A prospective naturalistic treatment study. *Bipolar Disord* 16:523–530, 2014.
- Strug LJ, Suresh R, Fyer AJ, Talati A, Adams PB, Li W, Hodge SE, Gilliam TC, Weissman MM: Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). *Mol Psychiatry* 15:166–176, 2010.
- Surguladze SA, Elkin A, Ecker C, Kalidindi S, Corsico A, Giampietro V, Lawrence N, Deeley Q, Murphy DG, Kucharska-Pietura K, Russell TA, McGuffin P, Murray R, Phillips ML: Genetic variation in the serotonin transporter modulates neural system-wide response to fearful faces. *Genes Brain Behav* 7:543–551, 2008.
- Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. *JAMA* 290:1033–1041, 2003.
- Warren BL, Iñiguez SD, Alcantara LF, Wright KN, Parise EM, Weakley SK, Bolaños-Guzmán CA: Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood. *J Neurosci* 31:10,347–10,358, 2011.
- Willis-Owen SA, Turri MG, Munafò MR, Surtees PG, Wainwright NW, Brixey RD, Flint J: The serotonin transporter length polymorphism, neuroticism, and depression: a comprehensive assessment of association. *Biol Psychiatry* 58:451–456, 2005.
- Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. *Prog Neuropsychopharmacol Biol Psychiatry* 26:383–386, 2002.
- Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: Reliability, validity and sensitivity. *Br J Psychiatry* 133:429–435, 1978.
- Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E: Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. *J Clin Psychopharmacol* 20:105–107, 2000.
- Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E: Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. *Biol Psychiatry* 50:323–330, 2001.

Address correspondence to:

Kiki D. Chang, MD

Division of Child and Adolescent Psychiatry

Stanford University School of Medicine

401 Quarry Road

Stanford, CA 94305-5719

E-mail: kchang88@stanford.edu